- Home
- KIO vs LYEL Comparison
KIO vs LYEL Comparison
Compare KIO & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | KIO | LYEL |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.1M | 490.1M |
| IPO Year | 2011 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KIO | LYEL |
|---|---|---|
| Price | $10.94 | $20.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $27.25 |
| AVG Volume (30 Days) | ★ 347.8K | 103.1K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.69 | $0.39 |
| 52 Week High | $12.83 | $45.00 |
Technical Indicators
Market Signals| Indicator | KIO | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 32.82 | 35.81 |
| Support Level | N/A | $15.82 |
| Resistance Level | $12.51 | $27.30 |
| Average True Range (ATR) | 0.16 | 2.04 |
| MACD | -0.03 | -0.39 |
| Stochastic Oscillator | 27.97 | 7.97 |
Price Performance
Historical ComparisonAbout KIO KKR Income Opportunities Fund
KKR Income Opportunities Fund operates as a closed-end registered management investment company. The Fund's main objective is to generate a high level of current income, with a secondary objective of capital appreciation. The company invests in a portfolio of loans and fixed-income instruments of U.S. and non-U.S. issuers. The company will invest at least 80% of its Managed Assets in loans and fixed-income instruments or other instruments, including derivative instruments, with similar economic characteristics under normal market conditions.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.